Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports efficacy and safety results for vismodegib in patients with advanced basal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Basal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-04-30